Paper39679804
Targeted Delivery of c(RGDfk)-Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy.
Liu H and 7 others. Adv Sci (Weinh), 2025. Cited by 11 papers, by iCite.
Cite this record
ConductScience Library. Targeted Delivery of c(RGDfk)-Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy. Papers, record 39679804. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39679804
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Targeted Delivery of c(RGDfk)-Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Multiple Myeloma | Major topic |
| Liposomes | Major topic |
| Neutrophils | Major topic |
| Bone Marrow | Major topic |
| Oligopeptides | Major topic |
| Drug Delivery Systems | Major topic |
| Animals | |
| Mice | |
| Humans | |
| Tumor Microenvironment |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82070228 | National Natural Science Foundation of China | PubMed | ||
| 81773283 | National Natural Science Foundation of China | PubMed | ||
| 2024SWBS009 | Research Grant of Key Laboratory of Molecular Biological Targeted Therapies of the Ministry of Education | PubMed |
Source PubMed
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35339668 | Recent advances of nanodrug delivery system in the treatment of hematologic malignancies. | Semin Cancer Biol | 2022 | https://conductscience.org/library/papers/35339668 | PubMed |
| 2 | 21057511 | Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. | Nat Immunol | 2010 | https://conductscience.org/library/papers/21057511 | PubMed |
| 3 | 37199393 | The role of the host-Neutrophil biology. | Periodontol 2000 | 2023 | https://conductscience.org/library/papers/37199393 | PubMed |
| 4 | 31776467 | Extramedullary multiple myeloma. | Leukemia | 2020 | https://conductscience.org/library/papers/31776467 | PubMed |
| 5 | 27418644 | Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. | Blood | 2016 | https://conductscience.org/library/papers/27418644 | PubMed |
| 6 | 35377708 | Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. | J Clin Oncol | 2022 | https://conductscience.org/library/papers/35377708 | PubMed |
| 7 | 38486995 | Biomimetic "Gemini nanoimmunoregulators" orchestrated for boosted photoimmunotherapy by spatiotemporally modulating PD-L1 and tumor-associated macrophages. | Acta Pharm Sin B | 2024 | https://conductscience.org/library/papers/38486995 | PubMed |
| 8 | 34536449 | Cell-based therapeutics for the treatment of hematologic diseases inside the bone marrow. | J Control Release | 2021 | https://conductscience.org/library/papers/34536449 | PubMed |
| 9 | 25822788 | IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. | Nature | 2015 | https://conductscience.org/library/papers/25822788 | PubMed |
| 10 | 18509199 | The role of the bone marrow in neutrophil clearance under homeostatic conditions in the mouse. | FASEB J | 2008 | https://conductscience.org/library/papers/18509199 | PubMed |
| 11 | 36873164 | Reprogrammed siTNFα/neutrophil cytopharmaceuticals targeting inflamed joints for rheumatoid arthritis therapy. | Acta Pharm Sin B | 2023 | https://conductscience.org/library/papers/36873164 | PubMed |
| 12 | 26707720 | Rutin Attenuates Carfilzomib-Induced Cardiotoxicity Through Inhibition of NF-κB, Hypertrophic Gene Expression and Oxidative Stress. | Cardiovasc Toxicol | 2017 | https://conductscience.org/library/papers/26707720 | PubMed |
| 13 | 39679804 | Targeted Delivery of c(RGDfk)-Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/39679804 | PubMed |
| 14 | 27269947 | Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/27269947 | PubMed |
| 15 | 30662556 | Redox Dual-Responsive and O2‑Evolving Theranostic Nanosystem for Highly Selective Chemotherapy against Hypoxic Tumors. | Theranostics | 2019 | https://conductscience.org/library/papers/30662556 | PubMed |
| 16 | 38438374 | Metabolic remodeling by the PD-L1 inhibitor BMS-202 significantly inhibits cell malignancy in human glioblastoma. | Cell Death Dis | 2024 | https://conductscience.org/library/papers/38438374 | PubMed |
| 17 | 25312543 | Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo. | J Control Release | 2014 | https://conductscience.org/library/papers/25312543 | PubMed |
| 18 | 31689086 | Overcoming the Reticuloendothelial System Barrier to Drug Delivery with a "Don't-Eat-Us" Strategy. | ACS Nano | 2019 | https://conductscience.org/library/papers/31689086 | PubMed |
| 19 | 30538704 | Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma. | Front Immunol | 2018 | https://conductscience.org/library/papers/30538704 | PubMed |
| 20 | 37719368 | LPS adsorption and inflammation alleviation by polymyxin B-modified liposomes for atherosclerosis treatment. | Acta Pharm Sin B | 2023 | https://conductscience.org/library/papers/37719368 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42966964 | Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42966964 | PubMed |
| 42322170 | Engineered Neutrophils in Translational Medicine: Gene Editing, Nanotechnology, and AI-Driven Clinical Breakthroughs. | Adv Healthc Mater | 2026 | https://conductscience.org/library/papers/42322170 | PubMed |
| 42288907 | Liposomal multimodal theranostics for bone disorders: from rational responsive delivery and biomimetic strategies to clinical translation. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/42288907 | PubMed |
| 41593686 | Hijacking the helpers: platelet and neutrophil trafficking in AML and therapeutic exploitation. | Exp Hematol Oncol | 2026 | https://conductscience.org/library/papers/41593686 | PubMed |
| 41471085 | Plasma Cell Myeloma: Biochemical Insights into Diagnosis, Treatment, and Smart Nanocarrier-Based Therapeutic Development. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/41471085 | PubMed |
| 41328335 | Neutrophil-based delivery platforms: from natural mechanisms to engineered therapeutics. | Theranostics | 2026 | https://conductscience.org/library/papers/41328335 | PubMed |
| 41159240 | Cancer targeting carfilzomib nanomedicine: a comprehensive review of delivery vehicles and efficacy. | Nanomedicine (Lond) | 2025 | https://conductscience.org/library/papers/41159240 | PubMed |
| 39679804 | Targeted Delivery of c(RGDfk)-Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/39679804 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39679804
GET https://conductscience.org/api/papers/v1/39679804/references?page=2